Composition :

Each tablet GLAMAROL®1 contains Glimepiride 1 mg

Each tablet GLAMAROL®2 contains Glimepiride 2 mg

Each tablet GLAMAROL®3 contains Glimepiride 3 mg

Each tablet GLAMAROL®4 contains Glimepiride 4 mg


Pharmacology :

Glimepiride is an active substance of GLAMAROL® tablets that is lowering blood sugar levels and belonging to the sulfonylurea class. Glimepiride works by stimulating the release of insulin from ß-pancreatic cells. In principle, Glimepiride dose affects blood sugar levels. The administration of Glimepiride begins with a low dose until the desired metabolic control is obtained.


Indication :

GLAMAROL® tablets are used in addition to diet and exercise to lower blood glucose in patients with type II diabetes (Non Insulin Dependent) where sugar levels are not adequately controlled with diet, exercise and weight loss.


Dosage :

  • Usually for initial dose given once daily 1 mg GLAMAROL® Dosage can be increased as needed. Increased doses should be based on blood glucose examination and should be gradual (step by step), example at 1-2 weeks intervals given the dose of GLAMAROL® tablets gradually as follows: 1 mg, 2 mg, 3 mg, 4 mg, 6 mg and at specific cases 8 mg. Usually the dose for patients with good diabetes control is 1-4 mg of GLAMAROL® tablets daily.
  • Divided dose: time and divided dose is determined by the doctor by considering the patient’s lifestyle. Normally, a single dose of Glimepiride is sufficient. Drugs should be taken as soon as possible before breakfast.
  • Adjustment of secondary doses: as diabetes control improves, insulin sensitivity increases so that the need for Glimepiride decreases. To prevent excessive reduction in blood sugar (hypoglycemia), consideration should be given to regular dose reduction or discontinuation of Glimepiride therapy. Dose adjustments are also considered if there is a change in body weight or lifestyle of the patient, or controls appear other factors that may result in the patient becoming hypoglycemia or hyperglycemia.
  • Another diabetes drug change to Glimepirde: no dose-link between Glimepirde and other oral blood-lowering drugs. The initial dose of Glimepiride (on replacement of other antidiabetic drugs with Glimepiride) is 1 mg daily. This applies also to the change in the maximum dose of other blood sugar-lowering drugs. Any increase in Glimepirde dose should be in accordance with the above dosing instructions (see initial dose and titration section). Consideration of potential and duration of action of previous blood-lowering drugs. It is important to discontinue treatment to avoid additive effects that may increase the risk of hypoglycemia
  • Use in combination with Metfromin: when blood sugar levels can not be adequately controlled with the maximum daily dose of Glimepiride (or antidiabetics containing Metformin alone), both drugs may be used simultaneously. In some cases, the dose of the prescribed drug remains unchanged. Treatment with additional drugs starts with a low dose and depends on blood levels, then can be increased gradually to a maximum daily dose. Combination treatment should start with medical supervision.
  • Supervision in combination with insulin: when blood sugar levels can not be adequately controlled with the maximum daily dose of Glimepirde, may be administered together with insulin. In this case the dose of Glimepirde remains. Insulin treatment begins with a low dose and can be increased according to the desired blood sugar level. Combination treatment should be initiated in medical supervision. Long-term effectiveness is monitored by checking Hb-A1c levels for example every 3-6 months. Giving Glimepiride in the short term may be sufficient during uncontrolled periods in patients who are usually well controlled with diet and exercise.


Presentation and Registration Number :

GLAMAROL® 1 Box, 5 strips @ 10 tablets; DKL0408013310A1

GLAMAROL® 2 Box, 5 strips @ 10 tablets; DKL0408013310B1

GLAMAROL® 3 Box, 3 strips @ 10 tablets; DKL0408013310C1

GLAMAROL® 4 Box, 3 strips @ 10 tablets; DKL0408013310D1







Categorised in:

This post was written by admin